Key Inclusion Criteria:

          1. Documented genetic ALK, ROS1, or NTRK1-3 alteration (point mutation, fusion,
             amplification) as identified by local testing in a Clinical Laboratory Improvement
             Amendments (CLIA) laboratory in the US or equivalently accredited diagnostic lab
             outside the United States (US) is required.

          2. Age <12 years.

          3. Prior cytotoxic chemotherapy is allowed.

          4. Prior immunotherapy is allowed.

          5. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer
             therapy to National Cancer Institute Common Terminology Criteria for Adverse Events
             (NCI CTCAE) Version 4.03 Grade less than or equal to 1.

          6. All subjects must have measurable disease by RECIST v1.1 or Response Assessment in
             Neuro-Oncology Criteria (RANO) criteria at time of enrollment.

          7. Subjects with a primary CNS tumor or CNS metastases must be neurologically stable on a
             stable or decreasing dose of steroids for at least 14 days prior to enrollment.

          8. Subjects must have a Lansky (< 16 years) or Karnofsky (≥ 16 years) score of at least
             50.

          9. Life expectancy greater than or equal to 12 weeks.

         10. Adequate hematologic, renal and hepatic function.

        Phase 2 Inclusion Criteria:

          1. Age 12 to <25 years

          2. Cohort Specific Inclusion Criteria:

               -  Cohort 1: Subjects with NTRK fusion gene positive (NTRK+) advanced solid tumors
                  (including primary CNS tumors), that are tropomyosin receptor kinase (TRK) TKI
                  naïve;

               -  Cohort 2: subjects with NTRK+ advanced solid tumors (including primary CNS
                  tumors), that are TRK TKI pre-treated;

               -  Cohort 3: subjects with tumors or ALCL characterized by other ALK/ROS1/NTRK
                  alterations or NTRK fusions without centrally confirmed measurable disease or not
                  otherwise eligible for Cohort 1 or 2.

          3. Subjects in Cohorts 1 and 2 must have prospectively confirmed measurable disease by
             BICR prior to enrollment.

        Key Exclusion Criteria (Phase 1 and Phase 2):

          1. Subjects with neuroblastoma with only bone marrow disease evaluable by bone marrow
             aspiration only.

          2. Major surgery within 14 days (2 weeks) of start of repotrectinib treatment. Central
             venous access (Broviac, Mediport, etc.) placement does not meet criteria for major
             surgery.

          3. Known active infections (bacterial, fungal, viral including HIV positivity).

          4. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut
             syndrome) or other malabsorption syndromes that would impact drug absorption.

          5. Any of the following cardiac criteria:

               -  Mean resting corrected QT interval (ECG interval measured from the onset of the
                  QRS complex to the end of the T wave) for heart rate (QTc) > 470 msec obtained
                  from three ECGs, using the screening clinic ECG machine-derived QTc value

               -  Any clinically important abnormalities in rhythm, conduction, or morphology of
                  resting ECG (e.g., complete left bundle branch block, third degree heart block,
                  second degree heart block, PR interval > 250 msec)

               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                  events such as heart failure, congenital long QT syndrome, family history of long
                  QT syndrome, or any concomitant medication known to prolong the QT interval

          6. Peripheral neuropathy of CTCAE ≥grade 2.

          7. Subjects being treated with or anticipating the need for treatment with strong CYP3A4
             inhibitors or inducers.